Current Potential Therapeutic Approaches against SARS-CoV-2: A Review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yadav, Dharmendra Kumar | - |
dc.contributor.author | Singh, Desh Deepak | - |
dc.contributor.author | Han, Ihn | - |
dc.contributor.author | Kumar, Yogesh | - |
dc.contributor.author | Choi, Eun-Ha | - |
dc.date.accessioned | 2021-12-09T00:41:09Z | - |
dc.date.available | 2021-12-09T00:41:09Z | - |
dc.date.created | 2021-11-29 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82900 | - |
dc.description.abstract | The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection and replication have been proposed. These medicines include inhibitors of serine protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2). The S protein of SARS-CoV-2 binds to the receptor in host cells. ACE2 inhibitors block TMPRSS2 and S protein priming, thus preventing SARS-CoV-2 entry to host cells. Moreover, antiviral medicines (including the nucleotide analogue remdesivir, the HIV protease inhibitors lopinavir and ritonavir, and wide-spectrum antiviral antibiotics arbidol and favipiravir) have been shown to reduce the dissemination of SARS-CoV-2 as well as morbidity and mortality associated with COVID-19. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Biomedicines | - |
dc.title | Current Potential Therapeutic Approaches against SARS-CoV-2: A Review | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000725778700001 | - |
dc.identifier.doi | 10.3390/biomedicines9111620 | - |
dc.identifier.bibliographicCitation | Biomedicines, v.9, no.11 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85119586654 | - |
dc.citation.title | Biomedicines | - |
dc.citation.volume | 9 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Yadav, Dharmendra Kumar | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordAuthor | Host-based therapy | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | SARS-CoV-2 cell entry inhibitors | - |
dc.subject.keywordAuthor | Virus-based therapy | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | TMPRSS2 | - |
dc.subject.keywordPlus | DRUG | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.